Form 13-F position report

ZEVRA THERAPEUTICS INC

Reported by Arete Wealth Advisors LLC

ZVRA CUSIP 488445206 Manager CIK 0001600151

Reported 69,769 shares, down 4,510 (6.1%) from the prior quarter.

Reported value -11.5%; share count -6.1% vs. the prior quarter.

Reduced
% of reported 13F value 0.04% This manager · Q4 2025
Shares 69,769 Quarter-end amount reported
Reported value $625,130 Fair value at quarter end
Consecutive quarters held 20 Through Q4 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 564000
2022-03-31 382000
2022-06-30 353000
2022-09-30 490000
2022-12-31 377711100
2023-03-31 453000
2023-06-30 406000
2023-09-30 389114
2023-12-31 526836
2024-03-31 458803
2024-06-30 374000
2024-09-30 545000
2024-12-31 649000
2025-03-31 561000
2025-06-30 659000
2025-09-30 706393
2025-12-31 625130
2026-03-31 617201
2026-06-30 920699
2026-09-30 705020

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ZEVRA THERAPEUTICS INC held by Arete Wealth Advisors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 64,009 -196 (-0.3%) 0.04% $705,020 2026-11-09
Q2 2026 Reduced 64,205 -2,192 (-3.3%) 0.06% $920,699 2026-08-11
Q1 2026 Reduced 66,397 -3,372 (-4.8%) 0.04% $617,201 2026-05-18
Q4 2025 Reduced 69,769 -4,510 (-6.1%) 0.04% $625,130 2026-02-13
Q3 2025 Reduced 74,279 -510 (-0.7%) 0.05% $706,393 2025-11-12
Q2 2025 Reduced 74,789 -65 (-0.1%) 0.05% $659,000 2025-08-14
Q1 2025 Reduced 74,854 -3,118 (-4.0%) 0.04% $561,000 2025-05-16
Q4 2024 Unchanged 77,972 0 (0.0%) 0.05% $649,000 2025-02-12
Q3 2024 Reduced 77,972 -441 (-0.6%) 0.05% $545,000 2024-11-14
Q2 2024 Reduced 78,413 -691 (-0.9%) 0.03% $374,000 2024-08-14
Q1 2024 Reduced 79,104 -1,329 (-1.7%) 0.04% $458,803 2024-05-16
Q4 2023 Reduced 80,433 -296 (-0.4%) 0.04% $526,836 2024-02-14
Q3 2023 Added 80,729 +1,147 (1.4%) 0.07% $389,114 2023-10-30
Q2 2023 Reduced 79,582 -2,708 (-3.3%) 0.04% $406,000 2023-08-09
Q1 2023 Unchanged 82,290 0 (0.0%) 0.04% $453,000 2023-05-01
Q4 2022 Added 82,290 +3,725 (4.7%) 0.03% $377,711,100 2023-02-06
Q3 2022 Reduced 78,565 -491 (-0.6%) 0.05% $490,000 2022-11-07
Q2 2022 Added 79,056 +3,124 (4.1%) 0.04% $353,000 2022-08-15
Q1 2022 Added 75,932 +14,978 (24.6%) 0.03% $382,000 2022-05-06
Q4 2021 Added 60,954 +4,427 (7.8%) 0.05% $564,000 2022-02-07
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

189 managers reported ZEVRA THERAPEUTICS INC for Q4 2025.

Managers reporting ZEVRA THERAPEUTICS INC in Q4 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 4,507,051 +469,897 < 0.01% $40,383,177 6 qtrs
Woodline Partners LP Reduced 3,450,844 -25,299 0.12% $30,919,562 8 qtrs
VANGUARD GROUP INC Added 3,305,207 +221,845 < 0.01% $29,614,655 20 qtrs
FMR LLC Added 2,393,493 +758,922 < 0.01% $21,445,699 16 qtrs
Nantahala Capital Management LLC Reduced 1,771,936 -200,000 0.52% $15,876,546 10 qtrs
STATE STREET CORPORATION Added 1,482,956 +55,665 < 0.01% $13,287,286 19 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,341,681 +41,341 < 0.01% $12,024,511 20 qtrs
MORGAN STANLEY Added 1,157,913 +601,963 < 0.01% $10,374,901 20 qtrs
MILLENNIUM MANAGEMENT LLC Added 1,134,358 +99,107 < 0.01% $10,163,848 6 qtrs
Legal & General Group Plc Added 1,097,988 +44,589 < 0.01% $9,837,973 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2025
Filed
February 13, 2026
Filing type
13F-HR
Position type
EQUITY

Voting authority reported

Sole
0
Shared
0
None
69,769

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.